Mahdi Hatami - Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Mojtaba Rashidi - Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Mahshid Naghashpour - Abadan university of medical sciences, Abadan, Iran
Sahar Golabi - Abadan University of Medical Sciences, Abadan, Iran
Fatemeh Maghsoudi - Abadan University of Medical Sciences, Abadan, Iran
Maryam Adelipour - Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Background and Aim: The diagnosis of COVID-۱۹ is an essential step toward controlling the pandemic. For this purpose, a series of laboratory methods have been developed. This study evaluated the efficiency of the ELISA method for COVID-۱۹ IgM and IgG detection. Materials and Methods: In this case-control study, ۴۶ blood samples from PCR positive COVID-۱۹ patients and ۴۹ samples from PCR negative COVID-۱۹ subjects were collected. Subsequently, the presence of IgM and IgG in all blood samples was assessed using the Pishtaz Teb ELISA kit. Results:  The data demonstrated that among ۴۹ PCR negative, ۴۰ (۸۱.۶%) were IgM negative and ۹ (۱۹.۱%) were IgM positive. Besides, out of the ۴۹ PCR-negative patients, ۴۲ (۸۵.۷%) and ۷ (۱۴.۳%) were IgG negative and positive, respectively. In ۴۶ PCR-positive individuals, ۴۰ (۸۷%) were IgM negative, while ۶ (۱۳ %) were IgM positive. Of the ۴۶ PCR-positive patients, ۲۴ (۵۲.۲%) were IgG negative, and ۲۲(۴۷.۸%) were IgG positive. Conclusion:  Our results showed that detection of SARS-CoV-۲ IgG and IgM using Pishtaz Teb ELISA kit is not enough for COVID diagnosis, but it can serve as a diagnostic RNA supplement to confirm infection with SARS-CoV-۲ in approved clinics and other scientific communities, owing to its easy, rapid, and inexpensive availability.

Antibody, COVID-۱۹, IgM/IgG, Patients, Antibody, COVID-۱۹, IgM/IgG, Patients